June 7, 2026 · Journal of cardiac failure · DOI: 10.1016/j.cardfail.2026.03.036

Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM

Listen to this summary

The authors aimed to evaluate the impact of mavacamten on disease-related symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) using the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ). In a phase 3 trial, they found that mavacamten significantly improved symptoms such as shortness of breath and tiredness compared to placebo, with a notable proportion of patients experiencing meaningful symptom relief. Additionally, the study highlighted a correlation between HCMSQ scores and echocardiographic parameters, suggesting a link between symptom burden and cardiac function.

Sara Saberi, Srihari S Naidu, Iacopo Olivotto, Albert A Hagège, Yue Zhong, Jenny Lam, Kathleen W Wyrwich, Jennifer T Fine, Chantal Dolan, Veleka Allen, Amy J Sehnert, Matthew Reaney

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play